People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

HUNTINGTON — GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza and Wegovy started as a way to treat diabetes but have since become popular tools for weight loss. Dr. Matthew Christiansen ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

Adam Gilden, MD, MSCE, is an associate director of the Obesity Medicine Fellowship at University of Colorado School of Medicine and associate director of the Colorado University Medicine Weight ...

Chetty, from the Yale University School of Medicine in New Haven, Connecticut, and colleagues examined advertising practices of websites selling compounded GLP-1 RAs, including semaglutide ...

The Pharmaceuticals division grew revenues by ~4%, to ~$50.3bn, while the diagnostics division's revenues fell by ~1% ... to semaglutide, tirzepatide, and a host of other clinical stage GLP ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Just over ...

"It is estimated that by 2030, 30 million GLP-1 ... 4 (range 37-77), and 56% were women. All patients were initially seen in a community setting. Of the seven with NAION, four were taking ...

On the Big Pharma front, Hims & Hers appears to be going head-to-head with makers of weight loss drugs like Novo Nordisk’s semaglutide ... events linked to GLP-1 drugs. Among the ad’s ...